|
|
HHSN292201500060U
|
$5,878,180
|
N/A
|
CONSTELLATION NEW ENERGY
|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
5R21CA205636-02
|
$202,275
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
(NSF: 2018 GENERAL SOCIAL SURV) ADDING GLOBAL HEALTH ITEMS TO THE 2018 GENERAL SOCIAL SURVEY
|
APC17004
|
$187,328
|
UNKNOWN, UNKNOWN
|
NATIONAL SCIENCE FOUNDATION
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-02
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-02
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
5R01CA206005-02
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-02
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
5R21CA205437-03
|
$168,236
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-02
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous (5R01 CA194617-02)
|
5R01CA194617-04
|
$412,607
|
TSAI, KENNETH
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
(PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention'
|
5R01CA179992-04
|
$909,181
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQB5)Molecular Wiring and Therapeutic Targeting of EGFR and PDGFR Signaling Netw
|
5R01CA185137-04
|
$882,372
|
CHAREST, ALAIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
5R01CA194663-03
|
$401,482
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-04
|
$714,297
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
01/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048377-24
|
$39,000
|
GADDE, KISHORE
|
LSU PENNINGTON BIOMEDICAL RESEARCH CTR
|
|
02/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048381-24
|
$68,181
|
EHRMANN, DAVID
|
UNIVERSITY OF CHICAGO
|
|
03/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048468-24
|
$68,181
|
Furlong, Kevin
|
THOMAS JEFFERSON UNIVERSITY
|
|
04/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048434-24
|
$68,181
|
Goldberg, Ronald
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
05/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Proj
|
U01DK048514-24
|
$68,181
|
HAZUDA, HELEN
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
06/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048375-24
|
$68,181
|
Dabelea, Dana
|
UNIVERSITY OF COLORADO DENVER
|
|
07/22 Diabetes Prevention Program Outcomes Study (DPPOS)Phase 3 Research Project
|
U01DK048437-24
|
$42,300
|
Horton, Edward
|
JOSLIN DIABETES CENTER
|
|
08/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048413-24
|
$68,181
|
Kahn, Steven
|
SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
|
|
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048411-24
|
$37,181
|
DAGOGO-JACK, SAMUEL
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
1 BASE PERIOD: HDRP MEETING AND WORK GROUP SUPPORT $27,711.89
|
261201400011I
|
$1,353,862
|
UNKNOWN, UNKNOWN
|
SCIENTIFIC CONSULTING GRO
|
|
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Project
|
U01DK048380-24
|
$68,181
|
Molitch, Mark
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
11/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048397-24
|
$68,181
|
NATHAN, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
13/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048404-24
|
$68,181
|
PI-SUNYER, XAVIER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048406-24
|
$68,181
|
MATHER, KIEREN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
|
5R01CA206539-02
|
$366,000
|
SHUREIQI, IMAD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
15-PGDH in Cholangiocarcinogenesis
|
5R01CA102325-11
|
$344,269
|
WU, TONG
|
TULANE UNIVERSITY OF LOUISIANA
|
|
15/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048387-24
|
$68,181
|
Magee, Michelle
|
MEDSTAR HEALTH RESEARCH INSTITUTE
|
|
16/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048443-24
|
$68,181
|
WATSON, KAROL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
17/22 DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPPOS) PHASE 3 - RESEARCH PROJE
|
U01DK048400-24
|
$40,220
|
White, Neil
|
WASHINGTON UNIVERSITY
|
|
18/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Project
|
U01DK048485-24
|
$68,181
|
GOLDEN, SHERITA
|
JOHNS HOPKINS UNIVERSITY
|
|
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048407-24
|
$68,181
|
Schade, David
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
20/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048349-25
|
$68,181
|
CRANDALL, JILL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
2017 & 2019 Glycobiology Gordon Research Conference & Gordon Research Seminar
|
R13DE026693-01
|
$5,000
|
TIEMEYER, MICHAEL
|
GORDON RESEARCH CONFERENCES
|
|
2017 Cancer Nanotechnology Gordon Research Conference and Gordon Research Seminar
|
1R13CA213845-01
|
$2,500
|
KABANOV, ALEXANDER
|
GORDON RESEARCH CONFERENCES
|
|
2017 Cholangiocarcinoma Foundation Annual Conference
|
1R13CA213778-01
|
$5,000
|
LINDSEY, STACIE
|
CHOLANGIOCARCINOMA FOUNDATION
|
|
2017 Directed Cell Migration Gordon Research Conference and Gordon Research Seminar
|
1R13CA213855-01
|
$2,000
|
MONTELL, DENISE
|
GORDON RESEARCH CONFERENCES
|
|
2017 Physical Science of Cancer Gordon Research Conference
|
1R13CA213578-01
|
$5,000
|
DISCHER, DENNIS
|
GORDON RESEARCH CONFERENCES
|
|
2017 Stem Cells and Cancer Gordon Research Conference and Gordon Research Seminar
|
1R13CA213446-01
|
$4,000
|
RUDOLPH, K. LENHARD
|
GORDON RESEARCH CONFERENCES
|
|
2017 Translation Machinery in Health & Disease Gordon Research Conference and Gordon Research Seminar
|
1R13CA213656-01
|
$4,000
|
ACKERMAN, SUSAN
|
GORDON RESEARCH CONFERENCES
|
|
2017 Viruses and Cells Gordon Research Conference and Gordon Research Seminar
|
R13AI129344-01
|
$2,500
|
DAMANIA, BLOSSOM
|
GORDON RESEARCH CONFERENCES
|
|
21/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048412-24
|
$68,181
|
Venditti, Elizabeth
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|